An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue samples of patients with ovarian cancer using PARPi, and to determine the cut off value of the HRD score algorithm suitable for the Chinese population, so as to provide evidence for the role of PARPi in ovarian cancer. The screening of the beneficiaries of maintenance therapy provides precise guidance and can be used as a reference for other cancer types.

Inclusion Criteria:

1. age ≥ 18 years;
2. high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer;
3. FIGO stage III or IV;
4. at least 6 cycles and no more than 9 cycles First-line platinum-containing chemotherapy;
5. CR or PR after chemotherapy;
6. ECOG 0-1;
7. sufficient biological samples for HRD score detection;
8. patients signed informed consent;
9. good bone marrow function.

Exclusion Criteria:

1. incomplete follow-up records of survival information;
2. unqualified biological sample quality control